David Crumpacker, MD
Psychiatry · Plano, TXNPI 1912996562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $286,639 of the $386,348 with a category attached, or 74.2%. It is spread thinly across 41 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2024 at $121,377 and has fallen 58.4% since, to $50,543 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,368 payments — averaging $282.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$78K
- Johnson & Johnson$69K
- Otsuka America Pharmaceutical, Inc.$67K
- Eisai Inc.$53K
- Avanir Pharmaceuticals, Inc.$53K
- Idorsia Pharmaceuticals US Inc$32K
- plus $33K from 35 others
What the payments were for
- Consulting fees$50,63013%
- Speaking & faculty fees$286,63974%
- Travel & lodging$25,6337%
- Food & beverage$23,4476%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$386,348 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $144,318 |
| TrintellixVortioxetine Hydrobromide | 166 | $108,192 |
| AuvelityDextromethorphan Hbr/Bupropion | 96 | $105,930 |
| IngrezzaValbenazine Tosylate | 11 | $92,834 |
| RexultiBrexpiprazole | 42 | $85,567 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $38,274 |
| QuviviqDaridorexant Hcl | 42 | $26,082 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 220 | $15,559 |
| Rivastigmine | 69 | $11,154 |
| Duloxetine Hcl | 315 | $9,384 |
| Lurasidone Hcl | 19 | $7,781 |
| AdderallDextroamphetamine/Amphetamine | 12 | $7,262 |
| Aripiprazole | 140 | $7,164 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,731 |
| BelsomraSuvorexant | 14 | $5,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $3,153 | $144,31815 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse | $4,623 | $121,186193 claims |
| Axsome Therapeutics, Inc.Auvelity | $77,989 | $105,93096 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $890 | $92,83411 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $67,398 | $85,56742 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $52,958 | $38,27423 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $31,809 | $26,08242 claims |
| MerckBelsomra | $136 | $5,73014 claims |
| Lilly USA, LLCOlanzapine | $71 | $5,05759 claims |
| Shire North American Group IncMydayis | $14 | $3,94712 claims |
| Almatica Pharma LLCSertraline Hcl | $358 | $1,740266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Plano
- Suresh SureddiPlano$2.2M
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.